MBX Biosciences to Participate in March Investor Conferences

Rhea-AI Summary

MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in two major investor conferences in March 2025.

The company's President and CEO, Kent Hawryluk, will deliver a podium presentation at the TD Cowen 45th Annual Healthcare Conference in Boston on March 3, 2025, from 10:30-11:00 a.m. ET, along with one-on-one meetings. Additionally, MBX will participate in the Jefferies Biotech on the Beach Summit in Miami Beach on March 12th, featuring one-on-one meetings.

Webcasts of the presentations will be available on the investors section of MBX Biosciences' website, with replay access available approximately two hours post-event and archived for roughly 90 days.

CARMEL, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the following investor conferences:

TD Cowen 45th Annual Healthcare Conference

Date: Monday, March 3, 2025
Format: Podium Presentation and 1x1 meetings
Time: 10:30 a.m. – 11:00 a.m. ET
Location: Boston, MA

Jefferies Biotech on the Beach Summit

Date: Wednesday, March 12^th
Format: 1x1 meetings
Location: Miami Beach, FL

Presentation webcasts can be accessed on the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 90 days.

About MBX Biosciences 
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; MBX 1416 for the treatment of post-bariatric hypoglycemia (PBH) in Phase 1 development; and an obesity portfolio that includes MBX 4291, with an IND filing anticipated in Q2 2025, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.

Media Contact:
Kate Burdick
Inizio Evoke Comms
kate.burdick@inizioevoke.com
860-462-1569

Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com

FAQ

When and where will MBX Biosciences present at the TD Cowen Healthcare Conference in March 2025?

MBX Biosciences will present at the TD Cowen Healthcare Conference in Boston on March 3, 2025, from 10:30-11:00 a.m. ET.

What type of sessions will MBX participate in at the Jefferies Biotech Summit in March 2025?

MBX Biosciences will participate in one-on-one meetings at the Jefferies Biotech on the Beach Summit in Miami Beach on March 12, 2025.

How long will the MBX Biosciences conference presentation webcasts be available online?

The webcasts will be archived on MBX Biosciences' website for approximately 90 days, with replay access available about two hours after each event.

Where can investors access MBX Biosciences' March 2025 conference presentation webcasts?

Investors can access the presentation webcasts through the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events.